We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As FDA panel experts gear up to debate the merits of Gilead’s Descovy for HIV prevention, the question doesn’t seem to be whether it’s worthy of an indication in men, the largest part of the market. It’s whether it should get a green light in women.